The present study included 150 obstetric caregivers recruited from 27 health facilities in Buea, Limbe and Tiko health districts, of whom, 62 (41.3%) were nurses, 56 (37.3%) midwives, 26 (17.3%) general medical practitioners and 6 (4%) were obstetricians (Fig 1).
Fig 1: Study Consort
Participants’ age ranged from 21 to 67 years with a mean age of 34.19 ±9.27 years. Most of the participants, 76 (50.7%) were in the age group 21 to 30 years. A great majority of the participants were females, 121 (80.6%). The mean work experience was 7.77 (±7.52) years with 50 (33.3%) caregivers having between one to two years of work experience and 43 (28.7%) having more than 10 years of work experience. Furthermore, a majority of the caregivers, 91 (60.7%) worked in unclassified healthcare facilities (Health centres), 46 (30.7%) in Primary healthcare facilities (District hospitals) and 13 (8.7%) in a (Secondary healthcare facilities) Regional Hospitals. (Table 2)
Table 2: Sociodemographic and characteristics of the study population (n=150)
Also, the majority of caregivers, knew about AMTSL, 146 (97.3%), reported using AMTSL, 141 (94.0%) and had received training on AMTSL, 126 (84.0%) notably with 73 (58.9%) at the Medical/nursing/midwifery School and 38 (30.6%) at job training workshops (Table 3)
Table 3: Training information of participants on AMTSL
Globally, only 73 (48.7%) caregivers had good knowledge of AMTSL (Fig 2), of whom 22.7% (34/150) were midwives, 12% (18/150) were general medical practitioners, 12% (18/150) were nurses and 2% (3/6) were Obstetricians (Fig 3).
Fig 2: Global or overall knowledge level on AMTSL
Fig 3: Distribution of good knowledge level on AMTSL per profession
Only 45.3% of the caregivers knew all the three components of AMTSL (66.7% of obstetricians, 55.4% of midwives, 46.2% of general medical practitioners and 33.9% of nurses). However, up to 94.6% of the caregivers knew of oxytocin as the first line uterotonic drug recommended for AMTSL, 91.1% knew that the recommended dose of the uterotonic of choice for AMTSL was 10 IU (of oxytocin) and 77.9% of them reporting IM route as the recommended route to administer the drug during AMTSL (Table 4).
Table 4: Knowledge of Caregivers on AMTSL (MCQs and Likert scale) (n=150)
Caregivers who reported using AMTSL were 13 times more likely to have good knowledge of AMTSL compared to those who reported not using it (AOR: 12.96, 95%CI: 1.12 - 150.3, p=0.04). The profession and training on AMTSL were confounders (Table 5).
Table 5: Determinants of good knowledge of AMTSL (n=150)
Insufficient staff coverage, 31 (22.8%), unavailability of drugs and/or equipment, 23 (19.9%) and lack of knowledge and training of the staff, 17 (12.5%) were the major challenges reported. Furthermore, the challenges varied significantly between caregivers (p=0.013) (Table 6).
Table 6: Challenges of caregivers to AMTSL practice (n=136)
Organization of training programs, seminars and workshops on AMTSL following the standard and updated guidelines was the major recommendation proposed by caregivers, 61 (45.9%). Provision of an adequate supply of oxytocin and other delivery equipment, 21 (15.8%) as well as improvement in staff coverage, 21 (15.8%) were both greatly recommended too (Table 7).
Table 7: Recommendations to improve AMTSL practice (n=133)
The use of Standard Operating Procedures (SOPs), charts and/or posters on AMTSL, 76 (69.7%) pasted on the walls in the maternity ward was the main reference guiding the caregivers’ practice of AMTSL. Only six per cent of caregivers reported using WHO or evidence-based practice guidelines to guard their practice of AMTSL. That notwithstanding up to 12 (11%) of respondents did not have any reference guide of their practice of AMTSL (Table 8).
Table 8: Reference guide of AMTSL practice (n=109)